DUSP14 Antibody

What is DUSP14 and what are its primary functions in cellular signaling?

DUSP14 is a dual-specificity phosphatase that plays a crucial role in the inactivation of MAP kinases. It specifically dephosphorylates ERK, JNK, and p38 MAP kinases, thereby regulating various cellular processes. DUSP14 also functions as a negative regulator in T-cell receptor (TCR) signaling by dephosphorylating the MAP3K7 adapter TAB1, leading to its inactivation . Additionally, DUSP14 negatively regulates TNF- and IL-1-induced NF-κB activation by dephosphorylating TAK1 at Thr-187, which is an essential step in these inflammatory signaling pathways . This phosphatase is also known by several alternative names including MKP6, MAP kinase phosphatase 6, MKP-1-like protein tyrosine phosphatase, and MKP-L .

What are the key specifications to consider when selecting a DUSP14 antibody?

When selecting a DUSP14 antibody, researchers should consider several critical specifications:

• Host and Clonality: Most available DUSP14 antibodies are rabbit polyclonal antibodies, which offer high sensitivity but may have batch-to-batch variation .

• Validated Applications: Ensure the antibody has been validated for your specific application. Common applications include Western blot (WB), immunohistochemistry (IHC-P), and immunocytochemistry/immunofluorescence (ICC/IF) .

• Species Reactivity: Verify cross-reactivity with your species of interest. Available antibodies typically react with human, mouse, and rat DUSP14 .

• Immunogen Information: Consider the specific region of DUSP14 used as the immunogen. Many antibodies are raised against recombinant fragments corresponding to amino acids 1-150 or 1-198 of human DUSP14 .

• Molecular Weight: DUSP14 has a predicted molecular weight of approximately 22 kDa, which should be confirmed in validation data .

How does the structure of DUSP14 relate to its enzymatic function?

DUSP14's structure consists of 198 amino acids in humans, with a sequence that includes the characteristic phosphatase catalytic domain. The protein contains a critical cysteine residue at position 111 (C111) that is essential for its phosphatase activity . Mutation of this residue to serine (C111S) creates an enzyme-inactive mutant that loses the ability to inhibit TNF- and IL-1-induced NF-κB activation . The protein structure includes a catalytic domain with the consensus sequence (H-C-X-X-G-X-X-R) found in the dual-specificity phosphatase family. The three-dimensional arrangement allows DUSP14 to recognize and dephosphorylate both threonine/serine and tyrosine residues on its substrates, particularly within MAP kinases and TAK1 . This dual specificity is critical for its regulatory function in multiple signaling pathways.

What are the optimal conditions for using DUSP14 antibodies in Western blot applications?

For optimal Western blot results with DUSP14 antibodies, researchers should follow these methodological guidelines:

• Sample Preparation: Prepare cell lysates with standard RIPA or NP-40 lysis buffers containing protease and phosphatase inhibitors to preserve DUSP14 integrity.

• Protein Loading: Load 20-40 μg of total protein per lane for cell lysates. For overexpression systems, 10-20 μg may be sufficient.

• Gel Percentage: Use 12-15% SDS-PAGE gels to achieve good resolution around the 22 kDa region where DUSP14 is expected.

• Antibody Dilution: The recommended dilution range for Western blot applications is 1:200-1:2,000, though this should be optimized for each specific antibody . For Abcam's antibody (ab272587), a concentration of 0.4 μg/mL has been successfully used .

• Blocking Conditions: 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Detection System: Either chemiluminescence or fluorescence-based detection systems are suitable, with horseradish peroxidase-conjugated anti-rabbit IgG commonly used as a secondary antibody .

• Expected Results: A band at approximately 22 kDa corresponding to DUSP14 should be detected . Validation data shows clear differential signal between control lysates and DUSP14 overexpression lysates .

What protocols are recommended for immunoprecipitation studies involving DUSP14?

For effective immunoprecipitation (IP) of DUSP14 in research contexts:

• Lysis Buffer Composition: Use mild lysis buffers (e.g., 20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA) with freshly added protease and phosphatase inhibitors.

• Pre-clearing: Pre-clear lysates with protein A/G beads for 1 hour at 4°C to reduce non-specific binding.

• Antibody Incubation: Incubate 1-2 μg of DUSP14 antibody with 500-1000 μg of pre-cleared lysate overnight at 4°C with gentle rotation.

• Co-IP Detection Strategy: For co-immunoprecipitation studies examining DUSP14 interactions with TAK1 or TRAF proteins, both overexpression systems and endogenous detection approaches have been validated . Endogenous interaction between DUSP14 and TAK1 is enhanced following TNF or IL-1 stimulation, making these stimulation conditions important for co-IP experiments .

• Controls: Include appropriate controls such as IgG control, input samples (5-10% of IP material), and where relevant, enzyme-inactive DUSP14(C111S) mutant which maintains protein-protein interactions while lacking phosphatase activity .

• Washing Conditions: Perform 4-5 washes with lysis buffer containing reduced detergent concentration to minimize background while preserving specific interactions.

What are the key considerations for immunohistochemistry using DUSP14 antibodies?

For successful immunohistochemistry (IHC) with DUSP14 antibodies:

• Tissue Fixation: Use 10% neutral-buffered formalin fixation for paraffin-embedded tissues. Optimal fixation duration is 24-48 hours.

• Antigen Retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is typically required. Heating at 95-100°C for 15-20 minutes is recommended.

• Blocking: Block with 5-10% normal serum (from the same species as the secondary antibody) with 1% BSA in PBS for 1 hour at room temperature to reduce background.

• Primary Antibody Dilution: For IHC applications, DUSP14 antibodies are typically used at dilutions ranging from 1:50-1:200 . Optimize for each specific antibody and tissue type.

• Incubation Conditions: Incubate with primary antibody overnight at 4°C in a humidified chamber for optimal results.

• Detection System: DAB (3,3'-diaminobenzidine) chromogen with horseradish peroxidase-conjugated secondary antibodies provides good visualization of DUSP14 expression.

• Positive Control Tissues: Small intestine tissue has been validated for DUSP14 expression and can serve as a positive control for IHC studies .

• Counterstaining: Hematoxylin counterstaining provides good nuclear contrast for evaluating cellular localization of DUSP14.

How can researchers address common issues with specificity when using DUSP14 antibodies?

To address specificity concerns with DUSP14 antibodies:

• Validation with Multiple Antibodies: Use antibodies targeting different epitopes of DUSP14 to confirm findings.

• Genetic Controls: Utilize DUSP14 knockdown or knockout samples as negative controls. The research by Zhang et al. demonstrated effective DUSP14 knockdown using RNAi plasmids, with RNAi plasmid 1 showing the most effective reduction in DUSP14 expression .

• Peptide Competition Assays: Pre-incubate the antibody with excess immunizing peptide to confirm signal specificity.

• Expression Controls: Use samples with known overexpression of DUSP14 as positive controls. Lane 3 in Western blot validation data from Abcam shows the expected band in DUSP14 overexpression lysates compared to vector control .

• Cross-Reactivity Assessment: Consider potential cross-reactivity with other DUSP family members due to sequence homology. Particularly examine other MKPs (MAP kinase phosphatases) which may share structural similarities.

• Molecular Weight Verification: Always confirm that observed bands match the expected molecular weight of DUSP14 (22 kDa) . Be alert to any unexpected bands that may indicate cross-reactivity or post-translational modifications.

What are the key considerations for analyzing DUSP14 expression in different cellular contexts?

When analyzing DUSP14 expression across different cellular contexts:

• Basal Expression Levels: DUSP14 expression varies across tissues and cell types. Establish baseline expression in your model system before experimental interventions.

• Stimulus-Induced Regulation: DUSP14 interaction with signaling partners (e.g., TAK1) increases following TNF or IL-1 stimulation . Consider examining both basal and stimulus-induced expression/interactions.

• Subcellular Localization: Evaluate the subcellular distribution of DUSP14 using fractionation techniques or immunofluorescence microscopy. This provides insights into its functional regulation and potential translocation events.

• Co-expression with Substrates: Assess the co-expression patterns of DUSP14 with its known substrates (ERK, JNK, p38, TAK1) to understand the physiological relevance of DUSP14 expression in specific contexts.

• Normalization Controls: Use appropriate housekeeping controls (β-actin has been validated) for quantitative comparisons across different samples .

• Post-translational Modifications: Consider potential post-translational modifications that might affect antibody recognition or DUSP14 function in different cellular contexts.

How can conflicting data on DUSP14 function be reconciled in experimental design?

To reconcile conflicting data on DUSP14 function:

• Pathway-Specific Effects: DUSP14 has distinct effects on different signaling pathways. While it strongly inhibits TNF- and IL-1-induced NF-κB activation, knockdown experiments showed it does not affect Sendai virus (SeV)-induced activation of NF-κB or the IFN-β promoter . Design experiments to evaluate pathway-specific effects.

• Cell Type Considerations: Compare findings across different cell types (e.g., 293 cells versus HeLa cells) as both have been validated for DUSP14 studies . Cell-type specific effects may account for some discrepancies in the literature.

• Dose-Dependent Effects: DUSP14's inhibitory effects on signaling pathways are dose-dependent . Carefully titrate DUSP14 expression levels to detect potential biphasic effects.

• Temporal Dynamics: Consider the temporal dynamics of DUSP14 activity. Some conflicting data may be explained by examining different time points after stimulation, as TNF and IL-1 stimulation enhance DUSP14-TAK1 interaction .

• Technical Approach Diversity: Use complementary techniques (e.g., reporter assays, biochemical assays, imaging) to verify findings through different methodological approaches.

• Substrate Specificity Analysis: Systematically evaluate DUSP14's effects on different substrates. It dephosphorylates both MAP kinases (ERK, JNK, p38) and other targets like TAK1 at Thr-187 .

How can DUSP14 antibodies be utilized in signaling pathway analysis beyond conventional techniques?

Advanced applications of DUSP14 antibodies in signaling pathway analysis include:

• Proximity Ligation Assays (PLA): This technique can visualize and quantify endogenous protein-protein interactions between DUSP14 and its binding partners (TAK1, TRAF6) with single-molecule resolution in fixed cells or tissues.

• Phospho-specific Co-detection: Multiplex immunofluorescence using DUSP14 antibodies together with phospho-specific antibodies against its substrates (phospho-TAK1 Thr-187, phospho-IκBα, phospho-IKKα/β, and phospho-TBK1) can reveal spatial and temporal relationships between DUSP14 and its targets.

• ChIP-seq Applications: For investigating potential nuclear roles of DUSP14 in transcriptional regulation, chromatin immunoprecipitation followed by sequencing can map genome-wide binding sites.

• Live-cell Imaging: When combined with appropriate tagging strategies, DUSP14 antibodies can be used for tracking dynamic changes in DUSP14 localization following stimulation with TNF or IL-1.

• Single-cell Analysis: DUSP14 antibodies can be adapted for mass cytometry (CyTOF) or flow cytometry to analyze cell-to-cell variability in DUSP14 expression and its correlation with activation states in heterogeneous cell populations.

What experimental approaches can elucidate the role of DUSP14 in inflammatory disease models?

To investigate DUSP14's role in inflammatory disease models:

• Tissue-specific Conditional Knockouts: Generate tissue-specific DUSP14 knockout models to assess its function in different inflammatory contexts without developmental compensation.

• Phosphatase Activity Modulation: Utilize the enzyme-inactive DUSP14(C111S) mutant as a dominant-negative approach in disease models to distinguish between scaffolding and enzymatic functions of DUSP14 .

• Cytokine Response Profiling: Measure the impact of DUSP14 modulation on cytokine production profiles in primary immune cells using multiplexed assays. Focus on TNF and IL-1 pathways where DUSP14 has established regulatory roles .

• In vivo Imaging: Develop reporter systems to visualize DUSP14 activity in inflammatory disease models using bioluminescence or fluorescence techniques.

• Therapeutic Targeting Strategies: Design peptide inhibitors or small molecules targeting the DUSP14-TAK1 interaction identified in co-immunoprecipitation studies . Test these interventions in inflammatory disease models.

• Pathway-specific Readouts: Utilize the established NF-κB reporter assays to measure the impact of DUSP14 modulation in disease-relevant primary cells . Compare effects on different inflammatory signaling branches.

How can DUSP14 phosphatase activity be accurately measured in experimental systems?

For precise measurement of DUSP14 phosphatase activity:

• In vitro Phosphatase Assays: Use purified recombinant DUSP14 with synthetic phosphopeptides derived from known substrates (TAK1 Thr-187 peptide) and measure phosphate release using malachite green or similar colorimetric assays.

• Substrate-specific Activity Assessment: Measure dephosphorylation of immunoprecipitated natural substrates (TAK1, ERK, JNK, p38) by recombinant DUSP14 using phospho-specific antibodies.

• Kinetic Analysis: Determine Km and Vmax values for different substrates to understand the substrate preference of DUSP14. This can help reconcile different findings regarding DUSP14's effects on various targets.

• Activity-based Probes: Develop activity-based probes that specifically label active DUSP14 in complex biological samples, allowing for quantification of enzymatically active protein rather than just total protein levels.

• Inhibitor Studies: Use general phosphatase inhibitors (e.g., sodium orthovanadate) and more selective inhibitors to assess the contribution of DUSP14 to total cellular phosphatase activity against specific substrates.

• Cellular Phosphorylation Dynamics: Monitor the kinetics of substrate dephosphorylation following stimulus withdrawal in systems with normal, depleted, or enhanced DUSP14 levels. The rate of dephosphorylation provides an indirect measure of DUSP14 activity.

How does DUSP14 compare functionally and structurally to other DUSP family members?

A comparative analysis of DUSP14 within the DUSP family reveals:

While DUSP14 shares the characteristic dual-specificity phosphatase catalytic domain with other family members, it has a distinct substrate profile and regulatory function, particularly its ability to dephosphorylate TAK1 at Thr-187 and negatively regulate NF-κB signaling . Unlike some larger DUSP family members, DUSP14 is relatively small (22 kDa) and lacks extended regulatory domains found in other MKPs.

What are the most effective research strategies for investigating DUSP14's role in therapeutic contexts?

For investigating DUSP14's therapeutic potential:

• Target Validation Approaches:

  • Use CRISPR/Cas9 genetic manipulation to modulate DUSP14 levels in disease-relevant cell types

  • Employ conditional transgenic mouse models expressing wild-type or C111S mutant DUSP14 in relevant tissues

  • Validate the correlation between DUSP14 expression/activity and disease severity in patient samples

• Drug Discovery Strategies:

  • Design high-throughput screening assays using purified DUSP14 and fluorogenic substrates

  • Develop structure-based drug design approaches targeting the catalytic site containing C111

  • Screen for molecules that modulate DUSP14-TAK1 interaction identified in co-immunoprecipitation studies

• Biomarker Development:

  • Investigate the ratio of phosphorylated to total TAK1 as a biomarker for DUSP14 activity in patient samples

  • Develop immunoassays for measuring DUSP14 protein levels in clinical specimens

  • Evaluate DUSP14 expression levels as potential predictors of response to anti-inflammatory therapies

• Delivery Approaches:

  • Explore cell-penetrating peptides for delivering DUSP14-mimetic molecules

  • Investigate tissue-specific delivery systems for DUSP14 modulators

  • Develop gene therapy approaches for controlled expression of DUSP14 in specific tissues

What experimental controls are essential when investigating DUSP14 phosphatase specificity?

Essential controls for investigating DUSP14 phosphatase specificity include:

• Substrate Controls:

  • Purified phosphorylated substrates (ERK, JNK, p38, TAK1) with defined phosphorylation states

  • Site-directed mutants of substrates where key phosphorylation sites are altered (e.g., TAK1 T187A)

  • Appropriate negative control substrates (proteins not known to be DUSP14 targets)

• Enzyme Controls:

  • Catalytically inactive DUSP14(C111S) mutant as a negative control

  • Heat-inactivated DUSP14 to control for non-enzymatic effects

  • Other DUSP family members to assess relative specificity

• Assay Validation Controls:

  • General phosphatase inhibitors (sodium orthovanadate) as positive inhibition controls

  • Titration series of known phosphatase standards for quantitative calibration

  • Time course controls to ensure measurements are made in the linear range of the assay

• Cellular Context Controls:

  • DUSP14 knockout or knockdown cells to establish baseline phosphorylation levels

  • Stimulus-specific controls (e.g., TNF, IL-1, SeV) to evaluate pathway specificity

  • Cell type comparisons (e.g., 293 vs. HeLa cells) to account for cell-specific effects

• Specificity Verification:

  • In vitro competition assays with multiple potential substrates

  • Phospho-proteomic analysis comparing wild-type vs. DUSP14-deficient cells

  • Dose-response relationships for both enzyme concentration and substrate concentration

By incorporating these comprehensive controls, researchers can rigorously establish DUSP14's true substrate specificity and avoid misattribution of phosphatase activities.

How can DUSP14 antibodies contribute to understanding post-translational regulation of phosphatases?

DUSP14 antibodies can advance our understanding of phosphatase regulation through:

• Modification-specific Antibodies: Developing antibodies that specifically recognize post-translationally modified forms of DUSP14 (phosphorylated, ubiquitinated, SUMOylated) can reveal regulatory mechanisms controlling its activity and stability.

• Conformational State Detection: Generating conformation-specific antibodies that distinguish between active and inactive DUSP14 states would provide tools to monitor its activation dynamics in live cells.

• Interaction Dynamics: Using DUSP14 antibodies in combination with proximity-based assays can map the temporal sequence of protein interactions following stimulation with TNF or IL-1, building on the observed enhanced interaction between DUSP14 and TAK1 after cytokine stimulation .

• Cross-talk Analysis: DUSP14 antibodies can help investigate potential cross-talk between different post-translational modifications that might synergistically regulate phosphatase activity.

• Turnover Studies: Pulse-chase experiments using DUSP14 antibodies can determine how different cellular conditions affect the half-life and degradation pathways of DUSP14, providing insights into regulation at the protein stability level.

What methodological approaches can reveal novel DUSP14 substrates beyond known targets?

To identify novel DUSP14 substrates:

• Substrate-trapping Mutants: Generate substrate-trapping DUSP14 mutants (e.g., C111S) that bind substrates but cannot complete the dephosphorylation reaction, allowing for stable interactions that can be identified by mass spectrometry .

• Phosphoproteomics: Compare phosphoproteomes of cells with normal, depleted, or overexpressed DUSP14 to identify differentially phosphorylated proteins as candidate substrates.

• Proximity-based Labeling: Use APEX2 or BioID fused to DUSP14 to biotinylate proteins in close proximity, potentially identifying transient substrate interactions that might be missed by conventional immunoprecipitation.

• In vitro Dephosphorylation Screens: Develop high-throughput screens using arrays of phosphopeptides derived from the human phosphoproteome to identify sequences that can be dephosphorylated by purified DUSP14.

• Computational Prediction: Use machine learning approaches trained on known DUSP14 substrates to predict additional targets based on sequence context, structural features, and cellular localization.

• Pathway-focused Analysis: Given DUSP14's established role in TNF and IL-1 signaling , focus screening efforts on additional components of these pathways that contain phosphorylated residues.

How can researchers design experiments to investigate potential non-catalytic functions of DUSP14?

To explore potential non-catalytic functions of DUSP14:

• Structure-Function Analysis: Generate a panel of DUSP14 mutants beyond the catalytic C111S mutation to identify domains involved in protein-protein interactions independent of phosphatase activity.

• Protein-Protein Interaction Mapping: Use techniques like yeast two-hybrid screening or proximity labeling with catalytically inactive DUSP14(C111S) to identify interaction partners that bind regardless of phosphatase activity .

• Competitive Displacement Assays: Design peptides corresponding to different regions of DUSP14 and test their ability to disrupt protein complexes, potentially identifying scaffolding regions.

• Rescue Experiments: In DUSP14 knockout systems, compare the ability of wild-type DUSP14 versus C111S mutant to rescue different phenotypes, which can differentiate between catalytic and non-catalytic functions .

• Subcellular Localization Studies: Investigate whether DUSP14 influences the localization of interacting proteins independently of its phosphatase activity, possibly serving as a scaffold or chaperone.

• Temporal Dynamics Analysis: Using live-cell imaging approaches, compare the recruitment kinetics of wild-type versus catalytically inactive DUSP14 to signaling complexes following stimulation with TNF or IL-1.